Author Correction: Targeted therapy in patients with PIK3CA-related overgrowth syndrome

Article metrics

Correction to: Nature https://doi.org/10.1038/s41586-018-0217-9, published online 13 June 2018.

In the interests of transparency, the authors wish to amend the ‘Competing interests’ statement of this Article to read: “A patent application (WO2017140828A1) has been filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS), Université Paris Descartes, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719 (alpelisib) in the treatment of PIK3CA-related overgrowth spectrum (PROS/CLOVES syndrome). G.C. is the inventor.” The original Article has been corrected online.

Author information

Correspondence to Guillaume Canaud.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.